MID-VOLUME · FEMALE-LED
exemestane Side Effects
exemestane (also sold as Aromasin) sits MID-VOLUME #230 of 524 by FAERS report count. Lead signal: FEMALE-LED - 99% of sex-coded reports are female (18,955 F / 214 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 20,856
- FAERS reports
FDA Adverse Event Reporting System extract for exemestane. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
exemestane reporting skew - 99% of sex-coded reports are female (18,955 F / 214 M). Volume band MID-VOLUME #230 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for exemestane (Aromasin) (20,856 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2003–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
FATIGUE leads 2,174 of 20,856 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (99% of sex-coded rows)
Age peak 45-64 (5,935 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (2,477 reports, 11.9%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 924 |
| DYSPNOEA | 502 |
| FATIGUE | 395 |
| DIARRHOEA | 352 |
| ASTHENIA | 349 |
| MALIGNANT NEOPLASM PROGRESSION | 345 |
| NAUSEA | 341 |
| ASCITES | 313 |
| VOMITING | 310 |
| COUGH | 304 |
| DECREASED APPETITE | 292 |
| SEPSIS | 276 |
| MALAISE | 275 |
| HEADACHE | 273 |
| FALL | 272 |
| ARTHRALGIA | 270 |
| INSOMNIA | 268 |
| DIZZINESS | 266 |
| PYREXIA | 266 |
| TACHYCARDIA | 265 |
Reactions in Hospitalization Reports
Hospitalization mid-share (5,181, 24.8%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| DYSPNOEA | 612 |
| FATIGUE | 590 |
| NAUSEA | 565 |
| DIARRHOEA | 560 |
| VOMITING | 441 |
| PYREXIA | 404 |
| ASTHENIA | 392 |
| MALIGNANT NEOPLASM PROGRESSION | 373 |
| PAIN | 365 |
| PNEUMONIA | 351 |
| COUGH | 339 |
| ANAEMIA | 333 |
| WEIGHT DECREASED | 307 |
| DECREASED APPETITE | 304 |
| MALAISE | 298 |
| PLEURAL EFFUSION | 290 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 280 |
| HEADACHE | 261 |
| ARTHRALGIA | 235 |
| STOMATITIS | 233 |
How to read exemestane FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 20,856 voluntary reports linked to exemestane (Aromasin), 2003-2025. Death is listed on 2,477 (11.9%). Hospitalization appears on 5,181 (24.8%). Top co-reported indication: Breast Cancer.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 99% of sex-coded reports are female (18,955 F / 214 M).
Read with exemestane
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 21,004 FAERS cases (Δ 148 heavier vs exemestane); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 20,677 FAERS cases (Δ 179 lighter vs exemestane); DEATH-HEAVY · HOSP-HEAVY · MALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 20,636 FAERS cases (Δ 220 lighter vs exemestane); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 20,544 FAERS cases (Δ 312 lighter vs exemestane); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 50.2 pp vs exemestane's DEATH-HEAVY): CASELOAD · HOSP-MID.
exemestane stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.